Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

New executive appointments at Synergy Vision

Eileen Gallagher and Karine Henderson take on new leadership roles

- PMLiVE

2021: the year of decentralisation in drug development

By Marie McCarthy

Health IT and Clinical Informatics for Improving Patient Care

Dr. Donald Rucker, National Coordinator at the Office of the National Coordinator for Health Information Technology (ONC Health IT), explores all things medical and clinical informatics and “Health IT.” Among other...

Impetus Digital

Bayer symbol

Bayer’s finerenone scores FDA priority review for chronic kidney disease

FDA priority review is based on data from the phase 3 FIDELIO-DKD trial

- PMLiVE

Takeda and KSQ Therapeutics to develop immune-based cancer treatments

Collaboration will utilise KSQ’s CRISPR-screening technology

- PMLiVE

Celltrion’s investigational mAb cuts COVID-19 recovery time

Patients treated with mAb recovered 3.4 to 6.4 days quicker compared to placebo

- PMLiVE

J&J could launch its single-dose COVID-19 vaccine in March

Chief scientific officer Paul Stoffels said J&J is aiming for one billion doses in 2021

- PMLiVE

Nucleus Global announces a trio of promotions

Dan Bridges is appointed as new chief executive officer

- PMLiVE

AstraZeneca’s focus on diagnosing and managing chronic kidney disease

People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care

The Lucid Group Futures Academy welcomes its 2021 cohort

This week Lucid welcomed its newest cohort of graduates onto the 2021 Futures Academy programme. The programme provides graduates with a 12-month structured medical writing training programme. It’s a chance...

Lucid Group Communications Limited

- PMLiVE

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs

- PMLiVE

Sinovac’s COVID-19 vaccine demonstrates 50.4% efficacy in Brazilian trial data

Updated data is lower than previously reported efficacy rate

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links